RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat lymphoma: drug duo takes on cancer
Disease control OngoingThis study tests whether a new drug combination (loncastuximab tesirine plus rituximab) works better than standard chemotherapy for adults with diffuse large B-cell lymphoma that has returned or not improved after initial treatment. About 440 participants will be randomly assigne…
Matched conditions: RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: ADC Therapeutics S.A. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New combo therapy shows promise for Tough-to-Treat lymphomas
Disease control OngoingThis early-stage trial tests a new three-drug combination (ibrutinib, rituximab, and bendamustine) in adults with certain types of non-Hodgkin lymphoma that have come back after prior treatment. The main goal is to find the safest dose of ibrutinib when given with the other two d…
Matched conditions: RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Kami Maddocks, MD • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug duo offers hope for Hard-to-Treat lymphoma
Disease control OngoingThis study tests a combination of two drugs, copanlisib and venetoclax, in about 48 adults with diffuse large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to find the safest dose and see how well the drugs shrink tumors. Participants must ha…
Matched conditions: RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC